구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | gene therapy (ADV/HSV-tk, ADV/HSV-tk (gene therapy)) The Methodist Hospital Research In…·Glioblastoma 42 trials |
|---|---|
Overview Program | ADV/HSV-tk (gene therapy) |
Overview Company | The Methodist Hospital Research Institute |
Overview Modality | CGT |
Overview Target | Glioblastoma |
Overview Indication | Glioblastoma; Anaplastic Astrocytoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral gene therapy |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | biomarkers in PCa patients undergoing hormonal therapy |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Antimetabolites synergize with non-genotoxic antibody drug conjugate conditioning in hematopoietic stem cell lentiviral gene therapy.. Hematopoietic stem cell transplantation (HSCT) of genetically engineered cells is a promising treatment modality for monogenic diseases. However, hematopoietic stem cell (HSC)-directed lentiviral vector (LV) gene therapies remain limited by genotoxicities associate… |
Clinical Safety signal | Antimetabolites synergize with non-genotoxic antibody drug conjugate conditioning in hematopoietic stem cell lentiviral gene therapy.. Hematopoietic stem cell transplantation (HSCT) of genetically engineered cells is a promising treatment modality for monogenic diseases. However, hematopoietic stem cell (HSC)-directed lentiviral vector (LV) gene therapies remain limited by genotoxicities associate… |
Clinical Selected reported efficacy | 4% |
Clinical Result source | ClinicalTrials.gov NCT03004183 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03004183 |
Preclinical Animal (cat.) | Mouse |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | gene therapy (ADV/HSV-tk, ADV/HSV-tk (gene therapy)) The Methodist Hospital Research In…·Glioblastoma 42 trials |
|---|---|
Overview Program | ADV/HSV-tk (gene therapy) |
Overview Company | The Methodist Hospital Research Institute |
Overview Modality | CGT |
Overview Target | Glioblastoma |
Overview Indication | Glioblastoma; Anaplastic Astrocytoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | lentiviral gene therapy |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | biomarkers in PCa patients undergoing hormonal therapy |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Antimetabolites synergize with non-genotoxic antibody drug conjugate conditioning in hematopoietic stem cell lentiviral gene therapy.. Hematopoietic stem cell transplantation (HSCT) of genetically engineered cells is a promising treatment modality for monogenic diseases. However, hematopoietic stem cell (HSC)-directed lentiviral vector (LV) gene therapies remain limited by genotoxicities associate… |
Clinical Safety signal | Antimetabolites synergize with non-genotoxic antibody drug conjugate conditioning in hematopoietic stem cell lentiviral gene therapy.. Hematopoietic stem cell transplantation (HSCT) of genetically engineered cells is a promising treatment modality for monogenic diseases. However, hematopoietic stem cell (HSC)-directed lentiviral vector (LV) gene therapies remain limited by genotoxicities associate… |
Clinical Selected reported efficacy | 4% |
Clinical Result source | ClinicalTrials.gov NCT03004183 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03004183 |
Preclinical Animal (cat.) | Mouse |
추천 비교
추천 비교